Annexon, Inc.
Annexon, Inc. (ANNX): 6 pipeline candidates · 2 upcoming catalysts · ~14 mo cash runway · 4 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
14.4 months
D/E 0.29
Lead: Phase 3
6 candidates
2 upcoming, next in ~408d
5 buys · 10 sells (180d)
A transparent, data-derived signal for Annexon, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$793.8M
Cash
$176.2M
Quarterly Burn
$46.8M
Runway
14.4 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (6 candidates)
| Drug | Phase |
|---|---|
| ANX005 | Phase 3 |
| ANX007 | Phase 3 |
| ANX009 | Phase 3 |
| ANX1502 | Phase 1 |
| tanruprubart | Phase 3 |
| Vonaprument | Phase 3 |
Upcoming Catalysts (2)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
214
Total value held
$770.0M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 11,913,178 | $66.0M |
| blackrock, inc. | 10,938,509 | $60.6M |
| fmr llc | 10,635,648 | $58.9M |
| bvf inc/il | 8,698,173 | $48.2M |
| state street corp | 6,919,255 | $38.3M |
| mak capital one llc | 4,724,043 | $26.2M |
| woodline partners lp | 4,674,274 | $25.9M |
| adage capital partners gp, l.l.c. | 4,300,000 | $23.8M |
| bank of america corp /de/ | 4,259,995 | $23.6M |
| nuveen, llc | 4,246,330 | $23.5M |
Showing top 10 of 214 institutional holders of Annexon, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Annexon, Inc.'s pipeline?
Annexon, Inc. (ANNX) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Annexon, Inc.'s lead drug candidate?
Annexon, Inc.'s most advanced tracked candidate is ANX005 (Phase 3) for Guillain-Barre Syndrome.
What is Annexon, Inc.'s next catalyst?
Annexon, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Multicenter, Randomized, Parallel-Group, Double-Masked, 2-Arm, Sham Controlled Study of t" — expected July 31, 2027.
What is Annexon, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Annexon, Inc. has approximately 14.4 months of cash runway.
What is Annexon, Inc.'s market capitalization?
Annexon, Inc.'s market capitalization is approximately $793.8M.
Get the full picture on Annexon, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.